Skip to main content
Fig. 6 | Biology Direct

Fig. 6

From: ANKRD29, as a new prognostic and immunological biomarker of non–small cell lung cancer, inhibits cell growth and migration by regulating MAPK signaling pathway

Fig. 6

Correlation analysis of ANKRD29 expression on immune cell infiltration and immunotherapy in NSCLC. A-B Three immune-related scores (ESTIMATE score, stromal score and immune score) (A) and immune cell enrichment scores (B) showed that ANKRD29 expression was positively correlated with the level of immune cell infiltration levels. C-E Data obtained from KM plotter website showed that patients with low expression of ANKRD29 indicated promising responses to anti-PD1, anti-CTLA-4 and PD-L1/Atezolizumab therapy (D-E), in line with the increased expression of ANKRD29 in ICB responders analyzed by ROC Plotter database (C). F-I Overexpression of ANKRD29 in cancerous cells enhanced the ability of Jurkat to kill SPC-A1 and H1975 cells. Representative crystal violet staining images of SPC-A1 and H1975 cells after co-culture with Jurkat cells (F, H). (G, I) Quantification data for (F, H), respectively. J Correlation analysis between ANKRD29 expression and cytotoxic T lymphocyte infiltration levels in NSCLC datasets from TIDE website. Bars are the mean value ± SD. ns = no significant. * P < 0.05, ** P < 0.01, *** P < 0.001

Back to article page

Biology Direct

ISSN: 1745-6150

Contact us